CMCT shares surged 54.8% to $12.35 on January 22, 2026, following the company’s announcement that it has finalized the sale of its consumer lending division to an undisclosed buyer for $280 million in cash. The transaction marks a strategic shift toward focusing on core technology and digital services operations.

The sale, completed on January 21, 2026, generated immediate investor optimism, with analysts citing improved balance sheet flexibility and reduced regulatory exposure as key catalysts. CMCT reported that the proceeds will be used to pay down debt and fund selective acquisitions in fintech infrastructure. The stock had traded at $7.98 before the news, reflecting persistent concerns over loan portfolio risks. With the divestiture now closed, the company expects to report a non-recurring gain of approximately $150 million in Q1 2026 earnings. Trading volume spiked to 12.4 million shares, nearly triple the 30-day average, signaling strong market interest.

OneMedNet Inc. shares surged following news that its partner MLHealth 360 received FDA clearance for the Scaida BrainCT-ICH, a machine learning-based diagnostic tool for intracerebral hemorrhage detection. The approval, announced January 22, 2026, marks a key milestone in advancing AI-powered neuroimaging solutions.

The Scaida BrainCT-ICH system uses artificial intelligence to analyze brain CT scans and identify signs of bleeding with high accuracy, aiming to reduce diagnosis time in emergency settings. MLHealth 360, a subsidiary of OneMedNet, developed the technology under a strategic collaboration focused on digital health innovation. The FDA’s 510(k) clearance allows the device to be marketed in the U.S. as a Class II medical device. OneMedNet’s stock climbed 18% in after-hours trading, reflecting investor optimism over commercialization potential. The company expects initial deployment in hospital radiology departments by mid-2026.

General Motors (GM-US) plans to move production of the next-generation Buick Envision SUV from China to its Kansas City Fairfax plant in Kansas, starting in 2028, amid pressure to localize vehicle manufacturing for the U.S. market. The company also indicated it may discontinue the all-electric Chevrolet Bolt, produced at the same facility, within about 18 months.

The shift follows U.S. President Trump’s tariffs on Chinese imports, which have increased costs for vehicles made abroad. Additionally, the administration eliminated the $7,500 federal tax credit for electric vehicles, reducing consumer demand. The Bolt uses batteries from China’s CATL and currently shares the assembly line with gasoline-powered Envision and Chevrolet Equinox models. GM said it may continue Bolt production if sales remain strong but will prioritize gas-powered models. The company previously announced plans to boost Equinox output at the Kansas plant by 2027 due to new tariffs on Mexican-made vehicles and parts. In 2025, Buick sold 42,000 Envision units, down 11% from the prior year, partly due to trade restrictions.

Moderna Inc. has suspended investments in new late-stage vaccine trials due to declining U.S. regulatory support and policy shifts under Health and Human Services Secretary Robert F. Kennedy Jr., CEO Stephane Bancel said on January 22, 2026. The decision reflects concerns over limited market access and reduced funding for mRNA vaccines.

Bancel told Bloomberg TV during the World Economic Forum in Davos that the U.S. market’s shrinking size—due to delayed approvals, weakened mandates, and policy reversals—undermines potential returns. Recent changes include ending COVID-19 vaccine recommendations for pregnant women and children, restricting state mandates, and cutting research funding. Moderna shares rose 10.16% in morning trading on January 22, 2026, amid the announcement.

U.S. consumer spending grew steadily in November 2025, with real personal consumption expenditures rising 0.3% month-over-month, matching October’s pace and supporting economic momentum ahead of the holiday season. The core Personal Consumption Expenditures (PCE) price index rose 0.2% monthly and 2.8% annually, slightly below September’s 2.9%, signaling inflation remains moderate and showing no clear evidence of tariff-driven price pressures.

The Bureau of Economic Analysis released delayed October and November data on January 22, 2026, due to a federal government shutdown. Nominal spending increased 0.5% in both months, consistent with expectations. Goods spending posted its largest gain since July 2025, driven by autos, apparel, and gasoline, while services growth slowed. Real disposable income showed minimal growth, and savings rates fell to 3.5%, the lowest since October 2022, indicating consumers are drawing down savings. Wage growth decelerated, with private-sector pay rising 4.1% year-over-year—the slowest since June 2025. Market participants expect the Federal Reserve to hold rates steady at its February meeting amid resilient demand, stable labor markets, and subdued inflation.

FactSet and Barclays have announced a multiyear agreement to provide market data services, effective immediately. The partnership will integrate FactSet’s data solutions with Barclays’ global investment banking and wealth management platforms, enhancing analytics capabilities for clients.

Under the terms of the deal, Barclays will leverage FactSet’s financial data, research tools, and portfolio analytics across its institutional client offerings. The collaboration aims to improve decision-making efficiency and data accuracy in trading and asset management. FactSet’s platform supports over 150,000 financial instruments globally, with real-time updates and historical depth. Barclays cited scalability and data reliability as key factors in selecting FactSet. The agreement follows broader industry trends toward integrated data ecosystems. No financial terms were disclosed. The partnership is expected to expand over the next three years, with integration milestones scheduled for Q2 2026 and Q4 2027.

Abbott Laboratories shares dropped 7% on January 22, 2026, after the company reported fourth-quarter earnings that fell short of expectations and provided a weaker-than-anticipated 2026 revenue outlook. The decline followed a fiscal 2025 full-year revenue of $53.8 billion, below analysts’ estimates of $54.2 billion, with adjusted EPS at $1.92 versus the expected $1.98. Investors reacted negatively to the guidance, which projected 2026 revenue growth of 3% to 4%, lower than the prior forecast of 5% to 6%.

The underperformance was driven by softer-than-expected results in Abbott’s Diabetes Care and Nutrition segments, where sales declined due to market pressures and pricing adjustments. The company cited ongoing challenges in global supply chains and increased competition in key markets. CEO Robert Ford stated during the earnings call that the company remains focused on innovation and cost efficiency but acknowledged near-term headwinds. Abbott’s stock closed at $102.45, down from $110.20 the previous day. The drop extended losses into early trading on January 23, 2026.

The U.S. Food and Drug Administration approved Guardant Health’s Guardant360 CDx as a companion diagnostic test for identifying patients with BRAF V600E-mutated metastatic colorectal cancer eligible for treatment with encorafenib and cetuximab. The approval, issued on January 22, 2026, supports the use of the liquid biopsy test to detect the genetic mutation in plasma samples.

Guardant360 CDx is a next-generation sequencing-based assay designed to identify actionable genomic alterations in non-invasive blood samples. The FDA clearance aligns with clinical trial data showing improved outcomes when targeted therapy is guided by molecular profiling. The test will be used alongside the combination regimen developed by Amgen and Array BioPharma, which demonstrated efficacy in patients with this specific mutation.

This marks the first FDA-approved liquid biopsy companion diagnostic for BRAF V600E in metastatic colorectal cancer. Guardant Health (GNTX) shares rose 4.7% following the announcement, reflecting investor optimism over expanded commercial opportunities in oncology diagnostics.

U.S. consumer prices rose 0.2% in November, matching expectations and showing continued moderation in inflation, according to data released by the Bureau of Labor Statistics on January 22, 2026. The annual inflation rate held steady at 3.1%, consistent with forecasts and signaling a stable trend in price pressures.

Core CPI, excluding food and energy, increased 0.2% month-over-month and 3.4% year-over-year, aligning with market estimates. Shelter costs rose 0.5% monthly, contributing significantly to the headline figure, while used car prices declined slightly. Energy prices dipped 0.1% as gasoline costs fell amid lower crude oil prices. The report supports the Federal Reserve’s stance on holding interest rates steady, with no immediate signals for rate cuts or hikes. Markets reacted calmly, with Treasury yields remaining near recent lows and equities trading flat. The data reinforces expectations of a soft landing for the U.S. economy, though labor market strength remains a key watchpoint.

Crypto custodian BitGo priced its initial public offering at $18 per share, valuing the company at approximately $2 billion, and is set to begin trading on the New York Stock Exchange on January 22, 2026, under the ticker BTGO. The upsized offering, above its initial range, signals strong investor demand amid a broader anticipated IPO supercycle in 2026.

The debut follows a period of weak capital markets and contrasts with recent crypto market headwinds, including stalled regulatory progress in Washington that has weighed on peers like Coinbase (COIN) and Circle (CRCL). Still, BitGo’s IPO may signal renewed confidence ahead of potential mega-IPOs from SpaceX, OpenAI, and Anthropic, with some eyeing trillion-dollar valuations. NYSE President Lynn Martin cited 2026 as a likely supercycle for IPO activity, with momentum expected to build through the second quarter. PitchBook estimates U.S. unicorns’ total value at $4.3 trillion as of December 2025, driven largely by AI-driven growth. Companies are expected to remain selective about timing their offerings based on market conditions.

Trafigura has sold its first cargo of Venezuelan crude oil under a 50-million-barrel supply agreement between the U.S. and Venezuela, with Spanish refiner Repsol set to receive the shipment in February 2026. The sale marks one of the first exports of Venezuelan oil to Europe since the U.S. secured an agreement with Caracas earlier this month.

The transaction is part of a broader effort led by Washington to facilitate Venezuelan oil exports through trading houses Trafigura and Vitol. Vitol is separately shipping a cargo to its Saras refinery in Italy and has also arranged sales to U.S. refiners Valero Energy and Phillips 66. Both firms are marketing Venezuelan crude to refineries in India and other regions. Trafigura declined to comment, while Repsol did not respond. The deal follows the U.S. securing control over Venezuela’s leadership and initiating diplomatic agreements to unlock oil exports.

Vanguard, the US-based asset manager overseeing approximately £9 trillion in assets, announced plans to sell £1.9 billion of UK equities held in its LifeStrategy funds, reducing domestic exposure amid growing investor preference for international diversification. The move, set to unfold between March and June 2026, reflects a strategic shift to lower "home bias" in its UK-focused funds.

The LifeStrategy funds currently allocate 25% of equity holdings and 35% of bond allocations to UK markets; those levels will drop to 20% and 20%, respectively. Vanguard cited increased confidence among UK investors in global markets as the rationale. The decision comes despite the FTSE 100’s strong 2025 performance—up 21.5% versus the S&P 500’s 16.4%—and follows Chancellor Rachel Reeves’ efforts to promote London as a top destination for listings and investment. Analysts say the move undermines government messaging, even as Vanguard supports broader retail investment initiatives launching in April.

Black Sheep Brewery, a Yorkshire-based craft beer producer, has been rescued from collapse through a £6.5 million acquisition by Paramount Retail Group, owner of Saltaire Brewery, in a pre-pack administration deal completed on January 22, 2026.

The rescue follows Black Sheep’s parent company filing for administrator appointment in November 2025 and comes after the brewery reported a £3.1 million loss in 2024 amid inflation, high borrowing costs, and weak demand. The deal includes a £2 million investment into Black Sheep and will preserve 145 jobs. A new entity, Great British Drinks Company, was formed to oversee the transition. Black Sheep had accumulated over £6 million in debt, including liabilities to HMRC, and had faced insolvency threats four times since the pandemic. The brewery was acquired in 2023 by Breal Capital for £5 million, which later consolidated it into Keystone Brewing Group. The craft beer sector has seen rising insolvencies, with Maazars reporting an 82% increase in brewery failures in 2023. Ravi Sharma of Great British Drinks Company emphasized restoring Yorkshire’s brewing heritage and rebuilding supplier relationships.

U.S. President Donald Trump warned Europe on January 22 that selling trillions of dollars in American stocks and bonds would trigger massive retaliation, asserting the U.S. holds all the leverage. The warning came during an interview with Fox Business Network at the World Economic Forum in Davos, though he did not specify potential actions.

The threat follows Trump’s abandonment of planned tariffs on eight European countries over Greenland sovereignty disputes, which had sparked speculation about retaliatory asset sales. A framework agreement has since been reached: the U.S. will delay new tariffs in exchange for missile deployment in Greenland, mineral rights restrictions to limit Chinese influence, and enhanced NATO presence.

Despite this, confidence has wavered among European investors. Denmark’s AkademikerPension announced a $100 million exit from U.S. Treasuries, while Greenland’s SISA pension fund is reviewing its U.S. equity exposure. However, analysts note most U.S. assets are held by private funds beyond government control. Treasury Secretary Scott Bessent downplayed concerns, calling Danish holdings negligible. As of November 2025, Europe held nearly 40% of foreign-owned U.S. Treasuries.

U.S. President Donald Trump's reversal on proposed tariffs against European allies triggered a global market rally on Jan. 22, reigniting the "TACO trade" as investors recalibrated expectations for his trade policy. After threatening 10% tariffs—rising to 25% by June 1—on eight European nations over Greenland, Trump cited progress in negotiations as reason to withdraw the threat during a CNBC interview at the World Economic Forum in Davos.

The shift reversed earlier market turmoil: on Jan. 21, stocks, bonds, and the dollar fell amid fears of renewed trade conflict. But with Trump’s softer tone, major U.S. indices surged Jan. 22, futures pointed to further gains, and Asian and European markets followed higher. Analysts noted the pattern mirrors last year’s “TACO” (Trump Always Chickens Out) dynamic, where aggressive rhetoric failed to materialize into lasting policy. Russell Mould of AJ Bell said the market’s relief reflects familiarity with Trump’s negotiating style. Yet caution remains: gold stabilized without sharp sell-offs, and defensive sectors like healthcare and tobacco outperformed, signaling lingering uncertainty. Alan Siow of Ninety One warned that while short-term sentiment may follow TACO logic, structural shifts in policy could emerge over time. Toni Meadows of BRI Wealth Management urged caution, citing the need for details on the Greenland framework and broader White House initiatives, including credit card rate caps. Investors now await the next major announcement.

U.S. stocks are adding to gains from January 21, 2026, as geopolitical tensions involving Greenland ease, boosting investor sentiment and fueling a broad rally across major indices. The S&P 500 rose 0.7%, the Nasdaq Composite gained 0.9%, and the Dow Jones Industrial Average climbed 0.6% by mid-afternoon trading on January 22, 2026. Market participants cited de-escalation in diplomatic talks between Arctic nations as a key driver of risk appetite.

The easing of concerns over territorial disputes in Greenland has reduced uncertainty in energy and shipping sectors, particularly benefiting commodities and infrastructure-related equities. The SPDR S&P 500 ETF Trust (SPY) and the Dow Jones Industrial Average (DIA) led the momentum, with both gaining more than 1% on the session. Analysts note that while the situation remains fluid, improved communication among Arctic powers has alleviated short-term volatility. Trading volume remained above average, signaling strong participation. Investors are now turning focus to upcoming U.S. inflation data scheduled for release on January 24, 2026.

Healthcare Triangle Inc. announced on January 22, 2026, a definitive agreement to acquire Teyame AI’s customer experience (CX) platforms, enhancing its digital health offerings. The transaction, expected to close in the second quarter of 2026, will integrate Teyame AI’s artificial intelligence-driven solutions into Healthcare Triangle’s existing suite of healthcare technology services.

The acquisition strengthens Healthcare Triangle’s position in patient engagement and operational efficiency tools. Teyame AI specializes in AI-powered CX platforms for healthcare providers, including virtual care navigation and automated patient support systems. Financial terms were not disclosed, but the deal is structured as an all-cash transaction. Healthcare Triangle shares rose 3.7% following the announcement, trading at $14.85 on Nasdaq. Teyame AI, a privately held company, has secured $28 million in venture funding since its founding in 2020. The integration plan includes retaining key Teyame AI personnel and maintaining operations in Austin, Texas.

Consumer spending increased 0.5% in November, surpassing expectations, as holiday season activity boosted demand despite elevated prices, according to a delayed Commerce Department report released January 22, 2026.

After adjusting for inflation, spending rose 0.3%. The Personal Consumption Expenditures (PCE) price index climbed 0.2% monthly, pushing the annual rate to 2.8%, aligning with Federal Reserve targets and economists’ forecasts. The data, which included previously unreleased October figures, highlighted continued inflationary pressure. Economists had anticipated a 0.2% monthly increase and a 2.8% yearly rate, per FactSet consensus. The report underscores resilience in consumer behavior amid high costs, though inflation remains above pre-pandemic norms.

TikTok has finalized a deal to divest its U.S. operations to a consortium of American investors, including Oracle, Silver Lake, and MGX, ahead of a January 22, 2026, closing date. The transaction, approved by President Donald Trump and Chinese leader Xi Jinping, establishes the TikTok USDS Joint Venture LLC to oversee data security, algorithm oversight, and content moderation under U.S. national security terms.

The investor group will hold 45% of the U.S. entity, with ByteDance retaining nearly 20%. Oracle will serve as the trusted technology partner, managing cloud infrastructure and auditing compliance, while also retraining a U.S.-based version of TikTok’s algorithm. ByteDance will have no access to U.S. user data or control over the algorithm. The deal values TikTok’s U.S. operations at approximately $14 billion, according to Axios and Vice President JD Vance. Users may transition to a new platform post-closing, though details remain unclear. This follows years of legal battles and executive actions, including a 2020 ban attempt under Trump and subsequent challenges under Biden. The agreement resolves longstanding concerns over data sovereignty and foreign influence.

Google DeepMind has acquired the CEO and seven top engineers from voice AI startup Hume AI under a new licensing agreement, according to Wired. The move aims to enhance Gemini’s voice features, with the team set to integrate into DeepMind’s research efforts. Hume AI will continue operating independently to license its technology to other firms, though financial terms were not disclosed.

Hume AI’s core innovation lies in its ability to detect user emotions through voice, demonstrated by its 2024 launch of the Empathetic Voice Interface. The startup has raised nearly $80 million and is projected to generate $100 million in revenue in 2026. This acquisition follows a trend of major AI firms targeting talent via acquihires—such as Google’s earlier pickup of Windsurf’s team and OpenAI’s acquisitions of Covogo and Roi—to avoid regulatory scrutiny. The Federal Trade Commission has signaled increased oversight of such deals. Meanwhile, voice AI remains a key battleground, with OpenAI developing audio-first devices and Meta advancing voice capabilities in Ray-Ban smart glasses. ElevenLabs recently reported $330 million in annual recurring revenue, underscoring growing demand for voice technologies.